The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Stacy Taylor Biography and Net Worth

SVP of Adaptive Biotechnologies

Stacy Taylor is the Senior Vice President, General Counsel of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. As General Counsel, Stacy leads Adaptive’s legal functions, including strategic transactions; commercial contracting; corporate governance; and compliance with healthcare, privacy and securities laws, as well as the protection, enforcement and strategic monetization of Adaptive’s intellectual property assets. She is a registered patent attorney with decades of business law and litigation experience. Stacy was previously a partner in several major law firms, most recently DLA Piper, where she co-chaired the firm’s global medical device practice. She has also served as senior assistant general counsel for five business units at BTG International (now Boston Scientific), a life sciences product company. In the late 1990s, Stacy co-founded Endicor Medical, an interventional cardiology device company which was later acquired by Medtronic. Stacy holds degrees in biological sciences and chemistry from California Polytechnic State University and is registered to practice law in Washington and California.

What is Stacy L. Taylor's net worth?: The estimated net worth of Stacy L. Taylor is at least $734,988.54 as of March 5th, 2024. Ms. Taylor owns 166,287 shares of Adaptive Biotechnologies stock worth more than $734,989 as of November 21st. This net worth approximation does not reflect any other investments that Ms. Taylor may own. Learn More about Stacy L. Taylor's net worth.
How old is Stacy L. Taylor?: Ms. Taylor is currently 64 years old. There are 7 older executives and no younger executives at Adaptive Biotechnologies. Learn More on Stacy L. Taylor's age.
How do I contact Stacy L. Taylor?: The corporate mailing address for Ms. Taylor and other Adaptive Biotechnologies executives is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. Adaptive Biotechnologies can also be reached via phone at (206) 659-0067 and via email at [email protected]. Learn More on Stacy L. Taylor's contact information.
Has Stacy L. Taylor been buying or selling shares of Adaptive Biotechnologies?: Stacy L. Taylor has not been actively trading shares of Adaptive Biotechnologies in the last ninety days. Most recently, Stacy L. Taylor sold 13,381 shares of the business's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $3.43, for a transaction totalling $45,896.83. Following the completion of the sale, the senior vice president now directly owns 166,287 shares of the company's stock, valued at $570,364.41. Learn More on Stacy L. Taylor's trading history.
Who are Adaptive Biotechnologies' active insiders?: Adaptive Biotechnologies' insider roster includes R. Adams (COO), Lance Baldo (Insider), Sharon Benzeno (Insider), Chad Cohen (CFO), Egon Durban (Director), David Goel (Director), Michelle Griffin (Director), Francis Lo (Insider), Jyoti Palaniappan (SVP), Chad Robins (CEO), Chad Robins (CEO), Harlan Robins (Insider), Julie Rubinstein (President), and Stacy Taylor (SVP). Learn More on Adaptive Biotechnologies' active insiders.
Are insiders buying or selling shares of Adaptive Biotechnologies?: During the last twelve months, insiders at the sold shares 6 times. They sold a total of 124,555 shares worth more than $429,325.41. The most recent insider tranaction occured on November, 18th when CFO Kyle Piskel sold 248 shares worth more than $1,235.04. Insiders at Adaptive Biotechnologies own 6.2% of the company. Learn More about insider trades at Adaptive Biotechnologies.
Information on this page was last updated on 11/18/2024.

Stacy L. Taylor Insider Trading History at Adaptive Biotechnologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/5/2024	Sell	13,381	$3.43	$45,896.83	166,287
3/6/2023	Sell	5,491	$8.57	$47,057.87	153,065
3/7/2022	Sell	1,569	$12.01	$18,843.69
12/22/2021	Sell	15,338	$30.00	$460,140.00
9/7/2021	Sell	495	$40.00	$19,800.00
6/30/2021	Sell	4,167	$41.42	$172,597.14
6/17/2021	Sell	4,166	$40.00	$166,640.00	16,077
4/30/2021	Sell	4,166	$41.93	$174,680.38	16,078
3/31/2021	Sell	4,167	$40.00	$166,680.00	16,078
2/26/2021	Sell	2,812	$55.53	$156,150.36	2,341
2/16/2021	Sell	16,250	$64.64	$1,050,400.00	17,550
1/29/2021	Sell	2,813	$56.51	$158,962.63	2,342
12/31/2020	Sell	6,530	$57.86	$377,825.80
11/23/2020	Sell	2,880	$46.31	$133,372.80	2,409
10/26/2020	Sell	2,880	$49.78	$143,366.40	2,410
9/24/2020	Sell	2,880	$47.78	$137,606.40	2,409
8/24/2020	Sell	2,880	$42.58	$122,630.40	2,409
7/24/2020	Sell	2,880	$36.03	$103,766.40	2,409
6/24/2020	Sell	2,880	$46.68	$134,438.40	2,409
5/26/2020	Sell	2,880	$42.00	$120,960.00	2,409
4/27/2020	Sell	19,580	$30.22	$591,707.60	9,610
1/8/2020	Sell	662	$30.00	$19,860.00	1,962

Stacy L. Taylor Buying and Selling Activity at Adaptive Biotechnologies

Adaptive Biotechnologies Company Overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Today's Range

Now: $4.42

$4.33

$4.57

50 Day Range

MA: $4.96

$4.00

$6.49

2 Week Range

Now: $4.42

$2.28

$6.70

Volume

1,819,296 shs

Average Volume

1,409,831 shs

Market Capitalization

$652.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45

Financial Prophecy

From Porter & Company | Ad